Low Rates of Nucleoside Reverse Transcriptase Inhibitor Resistance in a Well-Monitored Cohort in South Africa on Antiretroviral Therapy
- 1 February 2012
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (2), 313-320
- https://doi.org/10.3851/imp1985
Abstract
Background: The emergence of complex HIV-1 drug resistance mutations has been linked to the duration of time patients are on a failing antiretroviral drug regimen. This study reports on resistance profiles in a closely monitored subtype C infected cohort.Methods: A total of 812 participants were enrolled into the CIPRA-SA ‘safeguard the household’ study, viral loads were determined at 12-weekly intervals for 96 weeks. Virological failure was defined as either a 1,000 RNA copies/ml after week 24. Regimens prescribed were in line with the South African roll-out programme (stavudine, lamivudine, efavirenz or nevirapine). Viral RNA was extracted from patients with virological failure, and pol reverse-transcriptase PCR and sequence analysis were performed to determine drug-resistant mutations.Results: Virological failure was observed in 83 participants on the first-line regimen during the study period, of which 61 (73%) had HIV-1 drug-resistant mutations. The M184V mutation was the most frequent ( n=46; 65%), followed by K103N (46%) and Y181C (21%). Thymidine analogue mutations were infrequent (1%) and Q151M was not observed.Conclusions: Drug resistance profiles were less complex than has been previously reported in South Africa using the same antiretroviral drug regimens. These data suggest that frequent viral load monitoring limits the level and complexity of resistance observed in HIV-1 subtype C, preserving susceptibility to second-line options.Keywords
This publication has 23 references indexed in Scilit:
- Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trialThe Lancet, 2010
- Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1Journal of Virological Methods, 2010
- Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural TanzaniaBMC Infectious Diseases, 2009
- Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple TherapyAntimicrobial Agents and Chemotherapy, 2009
- The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapyAIDS, 2009
- A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequencesNucleic Acids Research, 2009
- Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1Journal of Virology, 2009
- Five‐year follow up of genotypic resistance patterns in HIV‐1 subtype C infected patients in Botswana after failure of thymidine analogue‐based regimensJournal of the International AIDS Society, 2009
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South AfricaClinical Infectious Diseases, 2008
- High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based RegimensAntimicrobial Agents and Chemotherapy, 2006